Dedifferentiated Liposarcoma: Causes, Symptoms, and Treatment

Dedifferentiated liposarcoma (DDLPS) is an aggressive fat-cell cancer that develops when a slower-growing fatty tumor transforms into a higher-grade, non-fatty sarcoma. It accounts for fewer than 2,500 new cases per year in the United States, making it rare even among sarcomas, and it most often appears deep in the abdomen or in the limbs and trunk.¹ Because the tumor can grow large before causing noticeable problems, understanding its biology, warning signs, and treatment landscape matters for anyone facing this diagnosis.

What DDLPS Actually Is

The word “dedifferentiated” describes a biological shift. Fat cells that were once well-differentiated, meaning they still looked and behaved somewhat like normal fat, lose that identity and become a more chaotic, non-fatty sarcoma. Pathologists define DDLPS as this transition from a well-differentiated liposarcoma (WDLPS) or atypical lipomatous tumor into a non-lipogenic sarcoma.¹ Under a microscope, you can sometimes see a sharp border between the fatty, well-differentiated component and the aggressive, dedifferentiated component. In other cases, the two types of tissue are interwoven in a mosaic pattern, which can make the diagnosis trickier.²

DDLPS arises most commonly in the retroperitoneum, the deep space behind the abdominal organs, and in the deep soft tissue of the limbs and trunk.¹ It is more common in men than women and has an annual incidence of roughly 0.21 cases per 100,000 people. One reason the tumor can be so problematic is that it may develop within a pre-existing well-differentiated liposarcoma that was either undetected or monitored for years before the shift happened. Roughly one in ten well-differentiated liposarcomas will undergo this dedifferentiation.³

The Molecular Drivers Behind the Disease

Unlike many cancers tied to smoking, diet, or other lifestyle factors, DDLPS is not linked to clear external causes. Instead, its roots are genetic, specifically in the amplification of certain genes on chromosome 12. The hallmark abnormality is extra copies of the MDM2 gene, which produces a protein that shuts down p53, one of the body’s most important tumor-suppressing mechanisms. When MDM2 is overproduced, the cancer cell effectively disables its own brakes.⁴ Another commonly amplified gene in the same chromosomal neighborhood is CDK4, which drives uncontrolled cell division.⁵

These two genes, MDM2 and CDK4, are present in both well-differentiated liposarcoma and DDLPS, so they do not fully explain why the tumor becomes more aggressive. Researchers have been looking for the additional changes that tip a slow-growing tumor into a dedifferentiated one. Candidates include new chromosomal rearrangements that create fusion genes, as well as alterations affecting receptor tyrosine kinases and other growth signals.⁶ Understanding these progression drivers is a major focus of current research, because they could open the door to treatments that block the transformation before it happens.

How DDLPS Presents and Why Symptoms Come Late

Symptoms of DDLPS depend heavily on where the tumor grows. In the retroperitoneum, where perhaps the majority of cases occur, the tumor has room to expand for months or even years without pressing on anything critical. People with retroperitoneal DDLPS often describe vague, non-specific complaints: a sense of abdominal fullness, mild discomfort, or changes in digestion. By the time symptoms become hard to ignore, the mass can be very large, sometimes pushing into the kidney, ureter, colon, or major blood vessels.⁷

In the extremities, the tumor is more likely to announce itself sooner as a palpable, growing mass. A case report described a 70-year-old woman who developed a giant soft-tissue mass in her lower leg over just a year, causing swelling and limiting her ability to move the joint.⁸ Weight loss, fatigue, and pain may occur in advanced cases regardless of location, but these are not reliable early warning signs. This is a tumor that is most often caught incidentally on imaging ordered for another reason, or when the mass finally grows large enough to feel or cause mechanical problems.

Getting to a Diagnosis

Imaging is the first step. On a CT scan, DDLPS typically appears as a mass with both fatty and non-fatty components. The non-fatty part usually shows soft-tissue density, though it can also appear fluid-like or mixed, which can sometimes confuse the picture.⁹ MRI can provide additional detail, particularly in distinguishing fat from non-fat elements and evaluating how the tumor relates to surrounding structures.

However, imaging alone cannot confirm the diagnosis. The gold standard is a tissue biopsy analyzed under a microscope, combined with molecular testing. Pathologists look for MDM2 amplification using a technique called fluorescence in situ hybridization, or FISH. In studies, 100% of well-differentiated and dedifferentiated liposarcomas tested positive for MDM2 amplification, making it an extremely reliable marker.¹⁰ Immunohistochemistry staining for MDM2 protein is another useful tool, with one study reporting 100% sensitivity and over 93% specificity for identifying DDLPS, particularly when the fatty component is not obvious.¹¹

This molecular testing is not just an academic exercise. DDLPS can look nearly identical to other high-grade sarcomas under the microscope, and getting the subtype right matters because DDLPS actually tends to carry a better prognosis than some of the tumors it mimics.¹² Getting the diagnosis wrong can mean the wrong treatment plan or an unnecessarily grim prognosis.

Surgery as the Cornerstone of Treatment

For localized DDLPS, surgery is the only potentially curative option. The goal is what surgeons call an oncologically complete resection: removing the entire tumor with a margin of normal tissue, ideally one to two centimeters, around it. This sounds straightforward, but it rarely is. In the retroperitoneum, the tumor often sits against the kidney, major vessels, and loops of bowel, making wide margins nearly impossible to achieve. Those anatomic constraints are a major reason local recurrence rates stay stubbornly high.¹

Because the tumor often invades adjacent organs, surgeons frequently need to remove one or more organs along with the tumor, a procedure called multivisceral resection. Pathology studies consistently find that the tumor has infiltrated surrounding organs in the vast majority of cases: clinically relevant organ infiltration was detected in over 84% of dedifferentiated liposarcomas in one series.¹³ Despite the apparent need, the benefit of routinely removing extra organs remains debated. A matched-cohort analysis found no significant difference in outcomes between multivisceral and tumor-only resections when the data were carefully balanced.¹⁴ The nuance is that if the tumor has genuinely grown into an organ, removing that organ is necessary for a complete resection, but prophylactically removing uninvolved organs does not appear to help.

One finding that consistently surfaces in the data is that outcomes are better when surgery is performed at a high-volume sarcoma center. These are rare tumors, and surgeons who see them regularly are more likely to plan the optimal operation and manage the complex recovery that follows. A referral to a specialized center before the first operation, rather than after a local recurrence, gives people the best chance.

The Role of Radiation Therapy

Radiation is often considered before surgery (neoadjuvant) for retroperitoneal DDLPS, with the goal of shrinking the tumor and reducing the chance it comes back locally. A study comparing neoadjuvant radiotherapy plus surgery against surgery alone found that radiation significantly improved recurrence-free survival, particularly in patients with dedifferentiated tumors. The protective effect was substantial: those receiving radiation were roughly 60% less likely to develop a local recurrence. Radiation did not, however, improve overall survival in this study.¹⁵

That disconnect, better local control without a clear survival gain, is a recurring theme in retroperitoneal sarcoma treatment. Local recurrence in DDLPS causes real suffering: pain, bowel obstruction, kidney problems, repeat surgeries. Reducing recurrence risk matters for quality of life even if the overall survival curve does not clearly shift. The decision about radiation is typically made tumor by tumor, weighing the potential to damage surrounding organs (particularly the bowel and kidneys) against the likely benefit, and it works best when planned by a multidisciplinary sarcoma team.

Chemotherapy and Newer Drug Approaches

For DDLPS that has spread beyond the reach of surgery, or that comes back in a way that cannot be resected again, systemic therapy becomes the main treatment. The standard first-line option remains doxorubicin, sometimes combined with ifosfamide. Two other drugs, trabectedin and eribulin, have been approved for recurrent liposarcomas.¹⁶ None of these drugs cure the disease, but they can slow progression and buy meaningful time.

Because MDM2 amplification is the defining genetic event in DDLPS, researchers have invested heavily in drugs that block the MDM2-p53 interaction, aiming to reactivate the p53 tumor suppressor. In cell lines and animal models these drugs work well, killing cancer cells by turning p53 back on. In people, the results have been more mixed. Multiple early-phase trials of MDM2 inhibitors failed to show clear benefit.¹⁷ One of the more promising agents, milademetan, achieved a disease control rate of about 58% in patients with DDLPS and a median progression-free survival of roughly 7 months, though it has yet to demonstrate the kind of dramatic tumor shrinkage that would change the standard of care.¹⁸

CDK4 inhibitors, already used in breast cancer, represent another logical target given the frequent CDK4 amplification in DDLPS. Palbociclib, the best-studied agent in this class for sarcoma, produced a median progression-free survival of about 18 weeks and kept roughly 57% of patients progression-free at 12 weeks in a phase 2 trial.¹⁹ The responses are mostly stabilizations rather than tumor shrinkage, which is a pattern that can still be clinically valuable but has limited the enthusiasm for CDK4 inhibitors as single agents.

Immunotherapy Combinations

Immune checkpoint inhibitors given alone have had modest results in DDLPS, with overall response rates in the single digits when used after first-line treatment. However, combining checkpoint inhibitors with anthracycline chemotherapy as a first-line regimen has shown a markedly higher response rate of around 52% in pooled data from early studies.²⁰ That number is based on small, early-phase trials and needs validation, but it has generated genuine excitement because a 52% response rate would be an order of magnitude better than checkpoint inhibitors alone.

Part of what makes immunotherapy complicated in DDLPS is the tumor’s immune landscape. When researchers profiled these tumors, they found that roughly half were “inflamed” (containing substantial immune cell activity) and half were immunologically cold.²¹ The inflamed tumors tend to carry more immune-suppressive regulatory cells and M2 macrophages, which create a paradox: the immune system sees the tumor but is being actively tamped down.²² Figuring out how to convert those suppressed immune responses into active tumor-killing is a key area of ongoing work.

Prognosis and What Drives It

The prognosis for DDLPS varies widely depending on whether the tumor is localized or has spread, where it is located, and whether complete surgical removal is possible. Population-level data from cancer registries show that tumors in the retroperitoneum carry a worse prognosis than those in the limbs, with median overall survival of roughly 46 months for retroperitoneal disease compared to about 60 months for non-retroperitoneal sites.²³

Across studies, the strongest prognostic factors are consistent. Surgical resection provides a dramatic survival benefit; in multivariate analyses, patients who undergo surgery have roughly a 70% lower risk of death compared to those who do not. Older age, larger tumor size, and more advanced stage at diagnosis all predict worse outcomes.²³ Younger age, the absence of metastases at diagnosis, and the absence of local recurrence are associated with better outcomes.²⁴

One counterintuitive finding in registry data is that chemotherapy is associated with worse survival. This almost certainly reflects selection bias rather than harm: patients who receive chemotherapy tend to be those with more advanced or aggressive disease that could not be managed with surgery alone. The data do not mean chemotherapy is harmful, but they do underscore how central surgery remains to outcomes in this disease.

Recurrence and Long-Term Surveillance

Local recurrence is the defining clinical challenge of DDLPS, especially in the retroperitoneum. The tumor has a persistent tendency to come back in the same area, even after apparently complete resection. Most relapses in soft-tissue sarcomas occur within the first two to three years after surgery, and the standard practice is to perform follow-up imaging every three to four months during that window, then gradually space out the intervals.²⁵ For retroperitoneal tumors, contrast-enhanced CT of the abdomen and pelvis is the recommended surveillance method.

There is some reassurance in the data about surveillance intensity. A study of well-differentiated retroperitoneal liposarcoma patients found that imaging every six months instead of every three would not have changed recurrence management in over 90% of patients.²⁶ That study focused on well-differentiated tumors rather than dedifferentiated ones, so its applicability to DDLPS specifically is debatable. Still, it suggests that the difference between three-month and six-month scans is often negligible in terms of real-world management decisions, which is useful to know when weighing the anxiety and radiation exposure that come with frequent imaging.

Quality of Life After Treatment

Major abdominal surgery with organ removal sounds devastating, and the recovery period is genuinely tough. But the long-term quality-of-life picture is more encouraging than many patients expect. A study collecting patient-reported outcomes from 127 people after retroperitoneal sarcoma resection found that their overall health scores were comparable to the general population, even at a median follow-up of nearly seven years. Physical functioning held up relatively well. The most persistent deficits were in emotional and social functioning, likely reflecting the psychological weight of living with a cancer that can recur rather than the physical aftermath of surgery.²⁷

In the first year after surgery, patients do experience a temporary worsening in pain and digestive symptoms like diarrhea, but these largely recover by the 12-month mark. One specific finding worth noting: nearly 41% of patients developed nerve-related pain associated with removal of the psoas muscle, a deep hip flexor that surgeons sometimes need to take to achieve clear margins.²⁸ This kind of nerve pain can be persistent and is worth discussing with the surgical team beforehand so expectations are realistic. Knowing that the overall trajectory bends back toward normalcy can help people face the first difficult months of recovery with some confidence.